Nasal Spray COVID-19 Vaccine Shows Promise in Animal Trials
TUESDAY, Jan. 19, 2021 -- A spritz instead of a shot to ward off COVID-19? Researchers report that a nasal spray vaccine against the new coronavirus shows promise in animal testing.
Rodents that were given two doses of the vaccine had antibody and T-cell responses that were strong enough to suppress SARS-CoV-2, the coronavirus that causes COVID-19.
The vaccine also reduced lung damage, inflammation and disease severity in the rodents, according to scientists from Lancaster University in England and Texas Biomedical Research Institute in San Antonio.
"We found that administering this vaccine through a nasal spray completely protected the animals from shedding the virus which causes transmission of the virus. This means the immunization of the upper respiratory tract through a nasal spray can prevent individuals from spreading the virus and developing infections elsewhere in the body," said study author Muhammad Munir, a Lancaster University virologist.
"Though the vaccine showed promising safety and efficacy in this animal model, human trials are still required to determine its applicability and to obtain regulatory approvals," Munir added in a university news release.
The nasal spray vaccine is based on a common poultry virus called the Newcastle Disease Virus (NDV), which can replicate in humans but is harmless. The research team engineered NDV to produce the spike proteins of the SARS-CoV-2 virus to prime the body's immune system to attack the coronavirus.
Their findings were published recently on BioRxiv, a preprint server for research that hasn't yet been peer-reviewed.
There are a number of advantages to a nasal spray vaccine, including it being noninvasive, triggering local immunity, and being an alternative for people who are afraid of needles or have blood clotting disorders, according to the researchers.
They noted that there's already a nasal spray vaccine for seasonal flu, so this type of vaccination has been proven to be effective.
A nasal spray vaccine for COVID-19 could provide a low-cost alternative for the developing world, because it could be produced using existing worldwide infrastructure for seasonal flu virus vaccines, the researchers suggested.
"The scalability and economical production make this vaccine candidate suitable for low- and middle-income countries," said study author Mohammed Rohaim, also from Lancaster University.
© 2021 HealthDay. All rights reserved.
Posted: January 2021
Further Support and Information on COVID-19
Read this next
TUESDAY, March 2, 2021 -- The U.S. Food and Drug Administration has approved the emergency use of Johnson & Johnson's single-shot coronavirus vaccine, adding a third weapon to...
TUESDAY, March 2, 2021 -- For Morgan Compton, 7, who has attended school remotely for nearly a year, the stress of the pandemic manifests itself in meltdowns. On one...
California Students Could Be Back in Classrooms by April New legislation could have many California's public school students returning to classrooms by April. The plan...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.